tbuckley/cabot-search huggingface dataset:
Abstract 6076: Long-term Follow-up Results of Percutaneous Catheter Intervention and Coronary Artery Bypass Graft Surgery for Kawasaki Disease: The Nationwide Survey in Japan
Authors: Masahiro Ishii, Hiromi Muta
Journal: Circulation (2008)

The purpose of this study is to clarify the long-term results of percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery for Kawasaki disease (KD) patients. The sub...
REPETITIVE SYNCOPE DURING PENTATHLON COMPETITION
Authors: Nora Sydo, Csulak Emese, István Szigyártó, Márk Kaufmann, Bálint Károly Lakatos, Attila Kovács, György Bárczi, Csilla Czimbalmos, Hajnalka Vágó, Dávid Becker, Thomas G. Allison, Bela Merkely
Journal: Journal of the American College of Cardiology (2020)
Leslie Brent: junior member of the “holy trinity of immunology”
Authors: John Illman
Journal: BMJ (2020)

Photo credit: Steve Back/Daily Mail/Shutterstock

As a doctoral student at University College London, Leslie Baruch Brent was the co-discoverer of acquired immune tolerance with his department head, Peter Medawar, and a doctoral researcher, Rupert Billingham. Their work revolutionised understanding of what was involved in transferring tissue from one person to another, providing the basis for tissue and organ transplantation—and the saving of hundreds of thousands of lives.

The three were dubbed the “holy trinity of immunology,” and their work underpinned research in the area for decades. The groundbreaking paper, “Actively acquired tolerance of foreign cells,” was published in Nature in 1953, the same year as Watson and Crick’s discovery of DNA.

After jointly winning the Nobel prize in 1960 with the Australian immunologist Frank Macfarlane Burnet, Medawar shared his prize money with Brent and Billingham and wrote: “I wish to make it absolutely clear that it is in no way a present but comes to you as of …
SYSTOLIC BLOOD PRESSURE RESPONSE TO EXERCISE DOES NOT PREDICT MORTALITY IN PATIENTS WITH ASYMPTOMATIC SEVERE AORTIC STENOSIS
Authors: Sonia Fortin Gamero, Anwesh Poosala, Amanda Bonikowske, Vuyisile Tlhopane Nkomo, Thomas G. Allison
Journal: Journal of the American College of Cardiology (2020)
OUTCOMES OF OPERATOR DIRECTED SEDATION AND GENERAL ANESTHESIA IN THE PEDIATRIC/CONGENITAL CATHETERIZATION LABORATORY: A STUDY USING DATA FROM THE IMPROVING PEDIATRIC AND CONGENITAL TREATMENT® (IMPACT) REGISTRY
Authors: Michael L. O'Byrne, Kevin Kennedy, James Steven, Kevin D. Hill, Reid Chamberlain, Marisa Millenson, Yoav Dori, Matthew J. Gillespie, Jonathan J. Rome, Andrew C. Glatz
Journal: Journal of the American College of Cardiology (2020)
“HEALTH ENHANCING HERBAL SUPPLEMENTS - SIDE EFFECTS MAY INCLUDE PACEMAKER IMPLANTATION”: A CASE OF SPONTANEOUSLY REVERSIBLE COMPLETE HEART BLOCK INDUCED BY HERBAL SUPPLEMENT USE
Authors: Daniel Jimenez, Prerna Gupta, Hilary Shapiro, Janet K. Han, Jesse Currier, Freny Mody
Journal: Journal of the American College of Cardiology (2020)
Infiltrating Mast Cell–Mediated Stimulation of Estrogen Receptor Activity in Breast Cancer Cells Promotes the Luminal Phenotype
Authors: Maria Teresa Majorini, Valeria Cancila, Alice Rigoni, Laura Botti, Matteo Dugo, Tiziana Triulzi, Loris De Cecco, Enrico Fontanella, Elena Jachetti, Elda Tagliabue, Claudia Chiodoni, Claudio Tripodo, Mario P. Colombo, Daniele Lecis
Journal: Cancer Research (2020)

Abstract Tumor growth and development is determined by both cancer cell–autonomous and microenvironmental mechanisms, including the contribution of infiltrating immune cells. Because the role of mast cells (MC) in this process is poorly characterized and even controversial, we investigated their part in breast cancer. Crossing C57BL/6 MMTV-PyMT mice, which spontaneously develop mammary carcinomas, with MC-deficient C57BL/6-KitW-sh/W-sh (Wsh) mice, showed that MCs promote tumor growth and prevent the development of basal CK5-positive areas in favor of a luminal gene program. When cocultured with breast cancer cells in vitro, MCs hindered activation of cMET, a master regulator of the basal program, and simultaneously promoted expression and activation of estrogen receptor (ESR1/ER) and its target genes (PGR, KRT8/CK8, BCL2), which are all luminal markers. Moreover, MCs reduced ERBB2/HER2 levels, whose inhibition further increased ESR1 expression. In vivo and in silico analysis of patients with breast cancer revealed a direct correlation between MC density and ESR1 expression. In mice engrafted with HER2-positive breast cancer tumors, coinjection of MCs increased tumor engraftment and outgrowth, supporting the link between MCs and increased risk of relapse in patients with breast cancer. Together, our findings support the notion that MCs influence the phenotype of breast cancer cells by stimulating a luminal phenotype and ultimately modifying the outcome of the disease. Significance: Mast cells impact breast cancer outcome by directly affecting the phenotype of tumor cells through stimulation of the estrogen receptor pathway.
TREATMENT USING NOAC VERSUS VKA AS A PREDICTOR OF LEFT ATRIAL THROMBUS FORMATION
Authors: Krzysztof Stanislaw Golba, Jolanta Pol-Romik, Jolanta Biernat, Eugeniusz Pilat, Michal Pieczara, Kinga Goscinska-Bis, Magdalena Cybulska, Katarzyna Sznajder, Danuta Loboda, Patrycja Nowak-Majda, Anna Szajerska-Kurasiewicz, Karolina Simionescu, Tomasz Roleder
Journal: Journal of the American College of Cardiology (2020)
COMPARISON OF RENAL DYSFUNCTION IN SYSTOLIC HEART FAILURE PATIENTS TREATED WITH SACUBITRIL-VALSARTAN OR ACE INHIBITOR/ANGIOTENSIN RECEPTOR BLOCKER
Authors: Nicholas Tan, Yihong Deng, Xiaoxi Yao, LIndsey Sangaralingham, Nilay Shah, Andrew Rule, John Burnett, Shannon Dunlay, Jeson Sangaralingham
Journal: Journal of the American College of Cardiology (2020)
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
Authors: John W. Stanifer, Sean D. Pokorney, Glenn M. Chertow, Stefan H. Hohnloser, Daniel M. Wojdyla, Samira Garonzik, Wonkyung Byon, Ziad Hijazi, Renato D. Lopes, John H. Alexander, Lars Wallentin, Christopher B. Granger
Journal: Circulation (2020)

Compared with the general population, patients with advanced chronic kidney disease have a >10-fold higher burden of atrial fibrillation. Limited data are available guiding the use of nonvitamin K antagonist oral anticoagulants in this population.We compared the safety of apixaban with warfarin in 269 patients with atrial fibrillation and advanced chronic kidney disease (defined as creatinine clearance [CrCl] 25 to 30 mL/min) enrolled in the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). Cox proportional models were used to estimate hazard ratios for major bleeding and major or clinically relevant nonmajor bleeding. We characterized the pharmacokinetic profile of apixaban by assessing differences in exposure using nonlinear mixed effects models.Among patients with CrCl 25 to 30 mL/min, apixaban caused less major bleeding (hazard ratio, 0.34 [95% CI, 0.14-0.80]) and major or clinically relevant nonmajor bleeding (hazard ratio, 0.35 [95% CI, 0.17-0.72]) compared with warfarin. Patients with CrCl 25 to 30 mL/min randomized to apixaban demonstrated a trend toward lower rates of major bleeding when compared with those with CrCl >30 mL/min (P interaction=0.08) and major or clinically relevant nonmajor bleeding (P interaction=0.05). Median daily steady-state areas under the curve for apixaban 5 mg twice daily were 5512 ng/(mL·h) and 3406 ng/(mL·h) for patients with CrCl 25 to 30 mL/min or >30 mL/min, respectively. For apixaban 2.5 mg twice daily, the median exposure was 2780 ng/(mL·h) for patients with CrCl 25 to 30 mL/min. The area under the curve values for patients with CrCl 25 to 30 mL/min fell within the ranges demonstrated for patients with CrCl >30 mL/min.Among patients with atrial fibrillation and CrCl 25 to 30 mL/min, apixaban caused less bleeding than warfarin, with even greater reductions in bleeding than in patients with CrCl >30 mL/min. We observed substantial overlap in the range of exposure to apixaban 5 mg twice daily for patients with or without advanced chronic kidney disease, supporting conventional dosing in patients with CrCl 25 to 30 mL/min. Randomized, controlled studies evaluating the safety and efficacy of apixaban are urgently needed in patients with advanced chronic kidney disease, including those receiving dialysis. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00412984.
Intranasal pain in a patient with Behçet’s disease
Authors: Koichi Tsunoda, Rinako Endo
Journal: BMJ (2020)

A 52 year old woman with Behcet’s disease presented with two to three days of severe pain in her left nostril. She had Behcet’s associated bowel, oral, and cerebral vasculitis and had been taking prednisolone for 20 years.

She reported occasional bouts of aphthous stomatitis (a known complication of Behcet’s disease) inside her mouth and on her lips, face, and hands, and said that topical corticosteroid was effective in these instances.

She also stated that blisters that were different from the aphthous ulcers sometimes appeared on her face, lips, and inside her mouth when the dose of steroid increased; these responded well to topical aciclovir so were assumed to be herpes simplex virus (HSV).

Six …
STATIN PRESCRIPTION RATES, ADHERENCE, AND ASSOCIATED CLINICAL OUTCOMES AMONG WOMEN WITH PERIPHERAL ARTERIAL DISEASE AND ISCHEMIC CEREBROVASCULAR DISEASE
Authors: Dhruv Mahtta, Sarah T. Ahmed, Michelle Lee, Fatima Rodriguez, Erin Michos, Dipti Itchhaporia, Khurram Nasir, Mahboob Alam, Hani Jneid, Christie M. Ballantyne, Laura Petersen, Salim Virani
Journal: Journal of the American College of Cardiology (2020)
Long-term storage of lipid-like nanoparticles for mRNA delivery
Authors: Pengxuan Zhao, Xucheng Hou, Jingyue Yan, Shi Du, Yonger Xue, Wenqing Li, Guangya Xiang, Yizhou Dong
Journal: Bioactive Materials (2020)

Lipid-like nanoparticles (LLNs) have been extensively explored for messenger RNA (mRNA) delivery in various biomedical applications. However, the long-term storage of these nanoparticles is still a challenge for their clinical translation. In this study, we investigated a series of conditions for the long-term storage of LLNs with encapsulation of mRNA. We evaluated the stability of LLNs with different concentrations of cryoprotectants (sucrose, trehalose or mannitol) under the conditions of freezing or lyophilization processes. Through in vitro and in vivo mRNA delivery studies, we identified the optimal storage condition, and found that the addition with 5% (w/v) sucrose or trehalose to LLNs could remain their mRNA delivery efficiency for at least three months in the liquid nitrogen storage condition.
PREVALENCE OF POST-TRANSPLANT MALIGNANCIES IN HEART TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Noman Lateef, Muhammad Shahzeb Khan, Muhammad Zain Farooq, Abdul Mannan Arif, Muhammad Shariq Usman, Tariq Jamal Siddiqi, Abdul Wahab, Safi U Khan, Ramki Doukky, Richard A. Krasuski
Journal: Journal of the American College of Cardiology (2020)
NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis
Authors: Lise Lurienne, Julie Cervesi, Lola Duhalde, Jean de Gunzburg, Antoine Andremont, Gérard Zalcman, Renaud Buffet, Pierre-Alain Bandinelli
Journal: Journal of Thoracic Oncology (2020)
Enhancement of TRAIL sensitivity with the proteasome inhibitor bortezomib in human esophageal and non-small cell lung carcinomas
Authors: Naoko Seki, Hideaki Yamana, Teruhiko Fujii, Kenji Nakano, Kazuo Shirouzu, Uhi Toh
Journal: Cancer Research (2006)

775  Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL ) is one of the most promising cytokines for anti-cancer therapy, which induces apoptosis in cancer cells by binding to death receptors DR4 and DR5. However, it has been reported that many tumor cell lines are either partially or completely resistant to TRAIL-mediated apoptosis despite of the expression of TRAIL receptors. Resistance results from a number of factors including increased Akt activity, overexpression of Bcl-2 family and c-FLIP, and combination therapies with several chemotherapeutic agents have been reported to increase the efficacy of TRAIL in these resistant cells. In this study we examined drug interactions between the proteasome inhibitor Bortezomib and TRAIL to induce apoptosis in various human esophageal cancer (EC) and none-small cell lung carcinoma (NSCLC) cell lines, including KE3∼10 (EC) which were established in our laboratory. Then mechanisms of the effects with the combination were assessed. Bortezomib enhanced TRAIL sensitivity markedly in a number of cell lines (EC: 11 out of 14 lines tested, NSCLS: 5 out of 7). Bortezomib and TRAIL synergized to kill TRAIL resistant tumor cell lines, including those with overexpressing Bcl-2 or increased Akt activity. One of the major effects of Bortezomib might be its high ability to enhance TRAIL-stimulated cleavage of caspase-8, which is correlated with increased cell-surface expression of TRAIL receptors DR4 and DR5, and somewhat reduced level of c-FLIP(L) expression in a part of cell lines. However increased expression of decoy receptors and c-FLIP(S) were also observed in these lines treated with Bortezomib. Modulator for the sensitization at the DISC level is further needed to investigate. On the other hand, a EC cell line TE8 showed no significant increase in levels of cleaved caspase-8 and Bid, but remarkable enhancement in induction of caspase-9/-3 cleavages, after the combined treatment as compared with the TRAIL treatment alone. It is suggested that effects on intrinsic apoptosis-pathway via mitochondria might be involved, and more crucial for TRAIL-sensitization of some tumor cells. Specific inhibitors for NFkB showed no remarkable effects on TRAIL sensitivity in all the cell lines tested. Our results suggest that Bortezomib and TRAIL may be useful combination therapeutically in EC and NSCLS.
Spiritual/religious struggle in hematopoietic cell transplant survivors.
Authors: Stephen Duane Watkins King, George Fitchett, Kenneth I. Pargament, Do Peterson, David A. Harrison, Rebecca H. Johnson, Paul J. Martin, Elizabeth Trice Loggers
Journal: Journal of Clinical Oncology (2013)

9573 Background: Spiritual/religious (SR) struggle (e.g., feeling abandoned or punished by God) has been associated with poorer coping and quality of life (QOL), greater depression and pain, and health declines in general cancer populations. Few studies have been conducted among survivors of hematopoietic cell transplantation (HCT). This study examined the prevalence and predictors of SR struggle in HCT survivors. Methods: Data were collected as part of an annual questionnaire of adult (age &gt;18 years) survivors of HCT at Fred Hutchinson Cancer Research Center in Seattle, WA. The 2011 survey included a SR module that incorporated the following items: Negative Religious Coping subscale of Brief RCOPE, subscales from the McGill QOL Questionnaire and the SF-36, Patient Health Questionnaire-8, disease information and socio-demographics. SR struggle was defined as any non-zero response on the Negative Religious Coping subscale of the Brief RCOPE. A multi-variable logistic regression model was used to determine factors associated with SR struggle. Results: Of 2113 returned surveys (52% response rate), 83% returned the SR module (n=1745) and of those 1586 were included in this analysis. Subjects were 49% female; 67% Christian and 20% Agnostic/Atheist/No preference; and 91% white. Mean age was 55 years; survivors ranged from 6 months to 40 years post-transplant. Primary indications for transplant were leukemia (49%), lymphoma (20%), and multiple myeloma (15%). Twenty-eight percent indicated SR struggle. In a multi-variable model, SR struggle showed statistically significant associations with age &gt;=65 years (odds ratio [OR] .57, p=.02); patient report of being religious only (OR 3.5, p&lt;.001) or spiritual only (OR 1.8, p&lt;.001) compared to being both religious and spiritual; depression (OR 1.1, p&lt;.001); and better social support (OR 0.77, p&lt;.001). Time since HCT, religious affiliation and race/ethnicity did not show statistically significant associations with SR struggle. Conclusions: SR struggle is common among HCT survivors, even years after HCT.Further study is needed to determine causal relations, longitudinal trajectory, impact of struggle intensity, and effects of SR struggle on health, mood and social roles for HCT survivors.
Metal/Metalloid Levels in Electronic Cigarette Liquids, Aerosols, and Human Biosamples: A Systematic Review
Authors: Di Zhao, Atul Aravindakshan, Markus Hilpert, Pablo Olmedo, Ana M. Rule, Ana Navas-Acien, Angela Aherrera
Journal: Environmental Health Perspectives (2020)

BACKGROUND: Electronic cigarettes (e-cigarettes) have become popular, in part because they are perceived as a safer alternative to tobacco cigarettes.An increasing number of studies, however, have found toxic metals/metalloids in e-cigarette emissions.OBJECTIVE: We summarized the evidence on metal/metalloid levels in e-cigarette liquid (e-liquid), aerosols, and biosamples of e-cigarette users across e-cigarette device systems to evaluate metal/metalloid exposure levels for e-cigarette users and the potential implications on health outcomes.METHODS: We searched PubMed/TOXLINE, Embase ® , and Web of Science for studies on metals/metalloids in e-liquid, e-cigarette aerosols, and biosamples of e-cigarette users.For metal/metalloid levels in e-liquid and aerosol samples, we collected the mean and standard deviation (SD) if these values were reported, derived mean and SD by using automated software to infer them if data were reported in a figure, or calculated the overall mean (mean ± SD) if data were reported only for separate groups.Metal/metalloid levels in e-liquids and aerosols were converted and reported in micrograms per kilogram and nanograms per puff, respectively, for easy comparison.RESULTS: We identified 24 studies on metals/metalloids in e-liquid, e-cigarette aerosols, and human biosamples of e-cigarette users.Metal/metalloid levels, including aluminum, antimony, arsenic, cadmium, cobalt, chromium, copper, iron, lead, manganese, nickel, selenium, tin, and zinc, were present in e-cigarette samples in the studies reviewed.Twelve studies reported metal/metalloid levels in e-liquids (bottles, cartridges, open wick, and tank), 12 studies reported metal/metalloid levels in e-cigarette aerosols (from cig-a-like and tank devices), and 4 studies reported metal/metalloid levels in human biosamples (urine, saliva, serum, and blood) of e-cigarette users.Metal/metalloid levels showed substantial heterogeneity depending on sample type, source of e-liquid, and device type.Metal/metalloid levels in e-liquid from cartridges or tank/open wicks were higher than those from bottles, possibly due to coil contact.Most metal/metalloid levels found in biosamples of e-cigarette users were similar or higher than levels found in biosamples of conventional cigarette users, and even higher than those found in biosamples of cigar users.CONCLUSION: E-cigarettes are a potential source of exposure to metals/metalloids.Differences in collection methods and puffing regimes likely contribute to the variability in metal/metalloid levels across studies, making comparison across studies difficult.Standardized protocols for the quantification of metal/metalloid levels from e-cigarette samples are needed.
Pilot trial of molecular profiling and targeted therapies in advanced thoracic malignancies: Non-small cell lung cancer, small cell lung cancer and thymic malignancies (CUSTOM).
Authors: Ariel Lopez-Chavez, Arun Rajan, Anish Thomas, Mark Raffeld, Liqiang Xi, Paul S. Meltzer, Regan M. Duffy, Svetlana Pack, Alan Sandler, Christopher L. Corless, Keith Killian, Carl Oberholtzer, Zied Abdullaev, Giuseppe Giaccone
Journal: Journal of Clinical Oncology (2012)

TPS7609 Background: For decades, clinical trial design strategies have relied upon the broad classification of tumors into tumor site and histopathology. Several lines of evidence have shown that a molecular approach to patient selection may be better in its capacity to improve patient outcomes. CUSTOM is an innovative clinical trial that allows for the parallel evaluation of multiple targeted therapies in molecularly selected patients with multiple cancer histological subtypes and the prospective evaluation of multiple molecular biomarkers. Methods: All patients with advanced lung cancer and thymic malignancies and a good performance status are eligible independently of previous lines of treatment. The trial begins with tumor biopsy and molecular profiling using a multi-platform approach to identify oncogenic alterations in more than 34 genes for treatment allocation (12 genes) and exploratory purposes. Depending upon the specific biomarker identified, patients are then triaged into 5 experimental arms. Erlotinib for sensitizing EGFR mutations; AZD6244 for KRAS, NRAS, HRAS and BRAF mutations; MK2206 for PIK3CA, AKT and PTEN mutations and PIK3CA amplification; Lapatinib for ERBB2 mutations or amplification; Sunitnib for KIT mutations and PDGFRA mutations and amplification. Patients not eligible for the experimental treatment arms are enrolled into a standard treatment arm. Upon disease progression patients are eligible for repeat biopsy and molecular profiling in order to identify molecular changes and mechanisms of resistance. All patients are followed until death. The primary endpoint is response rate and secondary endpoints include progression-free survival, duration of response and overall survival. With three disease types and five experimental drugs, there are 15 possible treatment arms which will be under active consideration. For each of these, the study will be conducted as an optimal two-stage phase II trial in order to rule out an unacceptably low 10% clinical response rate in favor of a modestly high response rate of 40%. As of January 11, 2012, two hundred and sixteen patients have been enrolled.
Interchangeable Insulins — New Pathways for Safe, Effective, Affordable Diabetes Therapy
Authors: Mariana P. Socal, Jeremy A. Greene
Journal: New England Journal of Medicine (2020)

Interview with Dr. Mariana Socal on draft guidance from the FDA aimed at promoting competition in the insulin market. (13:39)Download Draft FDA guidance would reduce barriers to marketing high-quality generic insulin in the United States by declaring that the evidence necessary for proving an insulin product "highly similar" to an existing product is sufficient for designating it as interchangeable.
ETHNIC DIFFERENCES IN COMPUTED TOMOGRAPHY AORTIC VALVE CALCIUM QUANTIFICATION IN PATIENTS WITH AORTIC STENOSIS
Authors: Ezequiel Guzzetti, Jin Kyung Oh, Mylène Shen, Marc Dweck, Kian Keong Poh, Amr E. Abbas, Ramy Mando, Gregg S. Pressman, Daniel Brito, Lionel Lloyd Tastet, Tania Pawade, Mariano Falconi, Diego Perez de Arenaza, William Kong, Edgar Tay, Philippe Pibarot, Jae-Kwan Song, Marie-Annick Clavel
Journal: Journal of the American College of Cardiology (2020)
BALLOON PULMONARY ANGIOPLASTY AS AN ALTERNATIVE TO THROMBOENDARTERECTOMY IN A PATIENT WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AND TYPE 2 CRYOCROBULINEMIA
Authors: Robert Zilinyi, Sanjum S. Sethi, Alexander Murphy, Joseph Ingrassia, Koji Takeda, Erika Berman Rosenzweig, Ajay Kirtane
Journal: Journal of the American College of Cardiology (2020)
Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers
Authors: Aris Liakos, Paraskevi Liakopoulou, Apostolos Tsapas
Journal: Annals of Internal Medicine (2020)

Source Citation Frykberg RG, Franks PJ, Edmonds M, et al. A multinational, multicenter, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy of cyclical topical wound oxygen therapy (TWO2) in the treatment of chronic diabetic foot ulcers: The TWO2 Study. Diabetes Care. 2019. [Epub ahead of print]. 31619393